TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:34
Applied Therapeutics Inc. ( APLT ) https://www.appliedtherapeutics.com
6.67USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
APLT
713.41%
SPY
32.74%
-66.40%
APLT
SPY
92.93%
APLT
0.00%
SPY
224.41%
APLT
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
572.87
523.44
0.56
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.57
53.74
-33.41
0.00
0.00
-8.85
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-161.13
100.00
-138.70
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
542.26
1086.42
0.00
Other Earnings and Cash Flow Stats:
Applied Therapeutics Inc. ( APLT ) Net Income TTM ($MM) is -76.41
Applied Therapeutics Inc. ( APLT ) Operating Income TTM ($MM) is -64.68
Applied Therapeutics Inc. ( APLT ) Owners' Earnings Annual ($MM) is 0.00
Applied Therapeutics Inc. ( APLT ) Current Price to Owners' Earnings ratio is 0.00
Applied Therapeutics Inc. ( APLT ) EBITDA TTM ($MM) is -65.42
Applied Therapeutics Inc. ( APLT ) EBITDA Margin is -138.70%
Capital Allocation:
Applied Therapeutics Inc. ( APLT ) has paid 0.00 dividends per share and bought back -47.044401 million shares in the past 12 months
Applied Therapeutics Inc. ( APLT ) has reduced its debt by 1.987 million USD in the last 12 months
Capital Structure:
Applied Therapeutics Inc. ( APLT ) Interest-bearing Debt ($MM) as of last quarter is 0
Applied Therapeutics Inc. ( APLT ) Annual Working Capital Investments ($MM) are 35
Applied Therapeutics Inc. ( APLT ) Book Value ($MM) as of last quarter is -18
Applied Therapeutics Inc. ( APLT ) Debt/Capital as of last quarter is -3%
Other Balance Sheet Stats:
Applied Therapeutics Inc. ( APLT ) has 49 million in cash on hand as of last quarter
Applied Therapeutics Inc. ( APLT ) has 71 million of liabilities due within 12 months, and long term debt 1 as of last quarter
Applied Therapeutics Inc. ( APLT ) has 84 common shares outstanding as of last quarter
Applied Therapeutics Inc. ( APLT ) has 0 million USD of preferred stock value
Academic Scores:
Applied Therapeutics Inc. ( APLT ) Altman Z-Score is -10.33 as of last quarter
Applied Therapeutics Inc. ( APLT ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Applied Therapeutics Inc. ( APLT ) largest shareholder is Knoll Capital Management LP owning 5474687 shares at 36.52 ($MM) value
Shendelman Shoshana(an insider) Sold 318573 shares of Applied Therapeutics Inc. ( APLT ) for the amount of $1717108.47 on 2024-03-14
7.89% of Applied Therapeutics Inc. ( APLT ) is held by insiders, and 72.95% is held by institutions
Applied Therapeutics Inc. ( APLT ) went public on 2019-05-14
Other Applied Therapeutics Inc. ( APLT ) financial metrics:
FCF:-57.00
Unlevered Free Cash Flow:0.00
EPS:-2.00
Operating Margin:-161.13
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:988.45
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Applied Therapeutics Inc. ( APLT ) :
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target central nervous system rare disease and diabetic complications in the United States. Its lead product candidate is AT-007 that has completed phase III for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.